Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
Anti-tumor necrosis factor α: originators < em > versus < /em > biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies
CONCLUSIONS: Real-life data demonstrated a similar safety profile between biosimilars and originators, but a reduced biosimilar retention rate at 24 months. Biosimilars could be considered a valid, safe, and less expensive alternative to originators, allowing access to treatments for a wider patient population.PMID:38115772 | DOI:10.4081/reumatismo.2023.1602 (Source: Reumatismo)
Source: Reumatismo - December 20, 2023 Category: Rheumatology Authors: C Gioia A Picchianti Diamanti R Perricone M S Chimenti A Afeltra L Navarini A Migliore U Massafra V Bruzzese P Scolieri C Meschini M Paroli R Caccavale P Scapato R Scrivo F Conti B Lagan à M Di Franco Source Type: research
